mTOR Cancer Research Results

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
1545- Api,    The Potential Role of Apigenin in Cancer Prevention and Treatment
- Review, NA, NA
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
558- ART/DHA,    Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
- Review, NA, NA
ROS↑, oncosis↑, Apoptosis↑, LysoPr↑, TumAuto↑, Wnt/(β-catenin)↑, AMP↓, NF-kB↓, Myc↓, CREBBP↓, mTOR↓, E-cadherin↑,
1532- Ba,    Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives
- Review, NA, NA
ROS↑, ER Stress↑, Ca+2↑, MMPs↓, Cyt‑c↑, Casp3↑, ROS↑, DR5↑, ROS↑, BAX↑, Bcl-2↓, MMP↓, Casp3↑, Casp9↑, P53↑, p16↑, P21↑, p27↑, HDAC10↑, MDM2↓, Apoptosis↑, PI3K↓, Akt↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IκB↓, IκB↑, BAX↑, Bcl-2↓, ROS⇅, BNIP3↑, p38↑, 12LOX↓, Mcl-1↓, Wnt?, GLI2↓, AR↓, eff↑,
2599- Ba,    Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, Apoptosis↑, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IKKα↓, IKKα↑, PI3K↓, MMP↓, TumAuto↑, TumVol↓, TumW↓,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
1416- Bos,    Anti-cancer properties of boswellic acids: mechanism of action as anti-cancerous agent
- Review, NA, NA
5LO↓, TumCCA↑, LC3B↓, PI3K↓, Akt↓, Glycolysis↓, AMPK↑, mTOR↓, Let-7↑, COX2↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, HIF-1↓, angioG↓, TumCP↓, TumCMig↓, NF-kB↓,
1844- dietFMD,    Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment
- Review, NA, NA
Risk↓, AMPK↑, Akt↓, mTOR↓, SIRT1↑, Hif1a↓, NRF2↓, SOD↑, ROS↑, IGF-1↓, p‑Akt↓, PI3K↑, GutMicro↑, OS↑, eff↝, ROS↑, TumCCA↑, *DNArepair↑, DNAdam↑,
683- EGCG,    Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy
- Review, NA, NA
AMPK↑, TumCP↓, P21↑, mTOR↓, COX2↓,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
1969- GamB,    Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
AntiTum↑, TumCI↓, Apoptosis↑, ROS↑, Cyt‑c↑, Akt↓, mTOR↓, TumCG↓, TumMeta↓,
2507- H2,    Hydrogen protects against chronic intermittent hypoxia induced renal dysfunction by promoting autophagy and alleviating apoptosis
- in-vivo, NA, NA
*RenoP↑, *ROS↓, *Apoptosis↓, *ER Stress↓, *CHOP↓, *Casp12↓, *GRP78/BiP↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *Beclin-1↑, *p62↓, *mTOR↓,
862- Lae,    Molecular mechanism of amygdalin action in vitro: review of the latest research
- Review, NA, NA
BAX↑, Casp3↑, Bcl-2↓, Akt↓, mTOR↓, p19↑, TumCCA↑, other↓,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
3480- MF,    Cellular and Molecular Effects of Magnetic Fields
- Review, NA, NA
ROS↑, *Ca+2↑, *Inflam↓, *Akt↓, *mTOR↓, selectivity↑, *memory↑, *MMPs↑, *VEGF↑, *FGF↑, *PDGF↑, *TNF-α↑, *HGF/c-Met↑, *IL1↑,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
1678- PBG,  5-FU,  sericin,    In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway
- in-vitro, CRC, Caco-2 - in-vivo, NA, NA
PI3K↓, Akt↓, mTOR↓, TumCP↓, Bcl-2↓, BAX↑, Casp3↑, Casp9↑, ROS↓, FOXO1↑, *toxicity∅, eff↑,
2944- PL,    Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells
- in-vitro, Thyroid, IHH4 - in-vitro, Thyroid, 8505C - in-vivo, NA, NA
ROS↑, selectivity↑, tumCV↓, TumCCA↑, Apoptosis↑, ERK↑, Akt↓, mTOR↓, neuroP↑, Bcl-2↓, Casp3↑, PARP↑, JNK↑, *toxicity↓, eff↓, TumW↓,
2341- QC,    Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
MMP2↓, MMP9↓, VEGF↓, Glycolysis↓, lactateProd↓, PKM2↓, GLUT1↓, LDHA↓, TumAuto↑, Akt↓, mTOR↓, TumMeta↓, MMP3↓, eff↓, GlucoseCon↓, lactateProd↓, TumAuto↑, LC3B-II↑,
2342- QC,    Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway
- in-vitro, HCC, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vivo, NA, NA
TumCP↓, HK2↓, Akt↓, mTOR↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,
39- QC,    A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells
- Analysis, NA, NA
ROS↑, GSH↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, MAPK↑, ERK↑, SOD↑, ATP↓, Casp↑, PI3K/Akt↓, mTOR↓, NOTCH1↓, Bcl-2↓, BAX↑, IFN-γ↓, TumCP↓, TumCCA↑, Akt↓, P70S6K↓, *Keap1↓, *GPx↑, *Catalase↑, *HO-1↑, *NRF2↑, NRF2↑, eff↑, HIF-1↓,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3405- TQ,  doxoR,    Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity and the underlying mechanism
- vitro+vivo, NA, NA
*cardioP↑, *NRF2↑, *HO-1↑, *ROS↓, *NQO1↑, *COX2↓, *NOX4↓, *GPx4↑, *FTH1↑, *p‑mTOR↓, *TGF-β↓,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
2365- VitD3,    Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H1975 - in-vivo, NA, NA
Glycolysis↓, Warburg↓, GLUT1↓, LDHA↓, HK2↓, PKM2↓, OCT4↓, SOX2↓, Nanog↓, PI3K↓, Akt↓, mTOR↓,
2425- γ-Toc,    Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis
- in-vitro, NA, MCF-7 - in-vivo, NA, NA
TumCG↓, GlucoseCon↓, ATP↓, lactateProd↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, Akt↓, p‑mTOR↓, cMyc↓,

Showing Research Papers: 1 to 28 of 28

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 28

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   CYP1A1↑, 1,   Ferroptosis↑, 1,   GSH↓, 2,   lipid-P↓, 1,   NRF2↓, 2,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 18,   ROS⇅, 1,   SOD↑, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 2,   EGF↓, 1,   MMP↓, 2,   e-Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   AMP↓, 1,   AMPK↑, 4,   cMyc↓, 3,   FABP4↑, 1,   GLO-I↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 5,   HK2↓, 3,   lactateProd↓, 4,   LDHA↓, 3,   PFK↓, 1,   PI3K/Akt↓, 2,   PKM2↓, 4,   PPARα↑, 1,   PPARγ↑, 1,   p‑S6↓, 1,   SIRT1↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 17,   p‑Akt↓, 6,   Apoptosis↑, 10,   Bak↑, 1,   BAX↑, 9,   Bcl-2↓, 8,   Bcl-xL↓, 1,   Casp↑, 2,   Casp3↑, 6,   Casp8↑, 1,   Casp9↑, 2,   p‑Chk2↑, 1,   Cyt‑c↑, 3,   DR5↑, 1,   Ferroptosis↑, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 2,   MDM2↓, 1,   Myc↓, 1,   oncosis↑, 2,   p27↑, 3,   p38↓, 1,   p38↑, 1,   survivin↓, 2,   Telomerase↓, 1,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↑, 1,   LC3B↓, 1,   LC3B-II↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 3,   DNMT1↓, 1,   HR↓, 1,   p16↑, 2,   P53↑, 4,   PARP↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   cycE1↓, 1,   p19↑, 1,   P21↑, 3,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State ⓘ

cMET↓, 1,   CREBBP↓, 1,   EMT↓, 4,   ERK↓, 5,   ERK↑, 2,   p‑ERK↓, 1,   FOXO1↑, 1,   Gli1↓, 1,   HDAC10↑, 1,   IGF-1↓, 3,   IGFBP3↓, 1,   Let-7↑, 1,   mTOR↓, 21,   p‑mTOR↓, 4,   Nanog↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   p‑P70S6K↓, 1,   p‑P90RSK↑, 1,   PI3K↓, 11,   PI3K↑, 1,   RAS↓, 1,   SOX2↓, 1,   STAT3↓, 5,   TumCG↓, 5,   Wnt?, 1,   Wnt↓, 3,   Wnt/(β-catenin)↓, 2,   Wnt/(β-catenin)↑, 1,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 1,   AP-1↓, 1,   Ca+2↑, 1,   CDK4/6↓, 1,   E-cadherin↑, 3,   GLI2↓, 1,   ITGB1↑, 1,   Ki-67↓, 1,   LysoPr↑, 1,   MMP2↓, 7,   MMP3↓, 1,   MMP9↓, 6,   MMPs↓, 1,   NCAM↑, 1,   p‑SMAD2↓, 1,   Snail↓, 2,   TGF-β↓, 2,   TIMP1↑, 1,   TIMP2↑, 2,   Treg lymp↓, 1,   TumCI↓, 5,   TumCMig↓, 5,   TumCP↓, 11,   TumMeta↓, 2,   Twist↓, 1,   VCAM-1↓, 1,   Vim↓, 2,   β-catenin/ZEB1↓, 2,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 3,   HIF-1↓, 3,   Hif1a↓, 4,   KDR/FLK-1↓, 1,   NO↓, 1,   TAMS↓, 1,   VEGF↓, 8,  

Barriers & Transport ⓘ

GLUT1↓, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   COX2↑, 1,   CXCR4↓, 1,   IFN-γ↓, 1,   IKKα↓, 1,   IKKα↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL1α↓, 1,   IL6↓, 3,   IL8↓, 1,   IκB↑, 1,   p‑IκB↓, 1,   MIP2↓, 1,   NF-kB↓, 7,   PGE2↓, 1,   TNF-α↓, 4,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 1,   eff↓, 2,   eff↑, 5,   eff↝, 1,   Half-Life↝, 1,   Half-Life∅, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

AR↓, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 3,   GutMicro↑, 1,   IL6↓, 3,   Ki-67↓, 1,   Myc↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 2,   chemoP↑, 1,   neuroP↑, 1,   OS↑, 3,   Risk↓, 1,   TumVol↓, 1,   TumW↓, 2,  
Total Targets: 202

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx?, 1,   Catalase↑, 1,   GPx↑, 1,   GPx4↑, 1,   HO-1↑, 2,   Keap1↓, 1,   NOX4↓, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 2,  

Metal & Cofactor Biology ⓘ

FTH1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↓, 1,   Casp12↓, 1,   HGF/c-Met↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↓, 1,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

FGF↑, 1,   mTOR↓, 2,   p‑mTOR↓, 1,  

Migration ⓘ

Ca+2↑, 1,   MMPs↑, 1,   PDGF↑, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1↑, 1,   Inflam↓, 2,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   memory↑, 1,   RenoP↑, 1,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 40

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
3 Quercetin
2 Artemisinin
2 Baicalein
2 EGCG (Epigallocatechin Gallate)
2 Naringin
1 Alpha-Lipoic-Acid
1 Apigenin (mainly Parsley)
1 Berberine
1 Boswellia (frankincense)
1 diet FMD Fasting Mimicking Diet
1 Gambogic Acid
1 Hydrogen Gas
1 Laetrile B17 Amygdalin
1 Metformin
1 Magnetic Fields
1 Propolis -bee glue
1 5-fluorouracil
1 sericin
1 Piperlongumine
1 Rosmarinic acid
1 Thymoquinone
1 doxorubicin
1 Urolithin
1 Vitamin D3
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:209  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page